Epiphora in lung cancer patients receiving docetaxel: a case series

BMC Research Notes

Nagio Takigawa¹  Satoshi Hasebe²  Hiromichi Yamane¹  Nobuaki Ochi¹  Tomoko Yamagishi¹ 

[1] Department of General Internal Medicine 4, Kawasaki Medical School, 2-1-80 Nakasange, Kita-ku, Okayama 700-8505, Japan;Department of Ophthalmology, Kawasaki Medical School, 2-1-80 Nakasange, Kita-ku, Okayama 700-8505, Japan

关键词: Ocular adverse event;    Epiphora;    Docetaxel;    Non-small cell lung cancer;   

Others  :  1132659
DOI  :  10.1186/1756-0500-7-322

 received in 2013-09-24, accepted in 2014-05-26,  发布年份 2014

【 摘 要 】

Background

Docetaxel is a key antineoplastic drug for treatment of non-small cell lung cancer. Ocular adverse events of docetaxel include epiphora (excess tearing) and conjunctivitis. Epiphora has been reported to be associated with canalicular and nasolacrimal duct stenosis, but it is not necessarily caused by lacrimal duct obstruction.

Case presentation

We encountered three Japanese non-small cell lung cancer patients who developed epiphora after the administration of docetaxel-based chemotherapy. One patient with lacrimal puncta stenosis showed improvement with probing and irrigation. The other two patients resolved following cessation of docetaxel or administration of artificial tears.

Conclusion

As epiphora can interfere with activities of daily life and negatively affect quality of life, it is important for thoracic oncologists to be aware of this adverse event.

【 授权许可】

   
2014 Yamagishi et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y, Berille J: Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
• [2]Cortes JE, Pazdur R: Docetaxel. J Clin Oncol 1995, 13:2643-2655.
• [3]Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V: Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002, 109:1188-1191.
• [4]Esmaeli B, Hidaji L, Adinin RB, Faustina M, Coats C, Arbuckle R, Rivera E, Valero V, Tu SM, Ahmadi MA: Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003, 98:504-507.
• [5]Chan A, Su C, de Boer RH, Gajdatsy A: Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 2013, 31:2123-2127.
• [6]Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M: Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 2010, 28:3299-3306.
• [7]Agustoni F, Platania M, Vitali M, Zilembo N, Haspinger E, Sinno V, Gallucci R, de Braud F, Garassino MC: Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders. Cancer Treat Rev 2014, 40:197-203.
• [8]Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E: Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol 2006, 24:3619-3622.
• [9]Kintzel PE, Michaud LB, Lange MK: Docetaxel-associated epiphora. Pharmacotherapy 2006, 26:853-867.
• [10]Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM, Newman RA: Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002, 120:1180-1182.
• [11]Leyssens B, Wildiers H, Lobelle JP, Gillis A, Paridaens R, Mombaerts I: A double-blind randomized phase II study on the efficacy of topical eye treatment in the prevention of docetaxel-induced dacryostenosis. Ann Oncol 2010, 21:419-423.
• [12]McCartney E, Valluri S, Rushing D, Burgett R: Upper and lower system nasolacrimal duct stenosis secondary to paclitaxel. Ophthal Plast Reconstr Surg 2007, 23:170-171.
• [13]Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008, 358:1663-1671.